JAC Advance Access originally published online on August 24, 2005
Journal of Antimicrobial Chemotherapy 2005 56(4):611-614; doi:10.1093/jac/dki291
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
Tigecycline: what is it, and where should it be used?
Antibiotic Resistance Monitoring & Reference Laboratory, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
* Tel: +44-20-8327-7223; Fax: +44-20-8327-6264; E-mail: david.livermore{at}hpa.org.uk
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials with activity against Gram-negative bacteria. It evades acquired efflux and target-mediated resistance to classical tetracyclines, but not chromosomal efflux in Proteeae and Pseudomonas. Cmax is low, but tissue penetration is excellent and the compound has shown equivalence to imipenem/cilastatin in intra-abdominal infection and to vancomycin plus aztreonam in skin and skin structure infection. Tigecycline may prove particularly useful for treatment of surgical wound infections, where both gut organisms and MRSA are likely pathogens. It is also likely to find a role in the treatment of infections due to multiresistant pathogens, including Acinetobacter spp. and ESBL producers, as well as MRSA and enterococci.
Keywords: tetracyclines , glycylcyclines , GAR-936
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Malli, I. Spiliopoulou, F. Kolonitsiou, Ch. Neocleous, D. Klapsa, K. Pantelidi, M. Panopoulou, S. Grapsa, E. Alepopoulou, I. Neonakis, et al. In vitro activity of tigecycline against Gram-positive cocci: a multicentre study in Greece J. Antimicrob. Chemother., August 27, 2008; (2008) dkn344v1. [Full Text] [PDF]
|
|
|
|
|
|
A. Capone, S. D'Arezzo, P. Visca, N. Petrosillo, and on behalf of the Gruppo Romano Acinetobacter bauma In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2008; 62(2): 422 - 423. [Full Text] [PDF]
|
|
|
|
|
|
T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., August 1, 2008; (2008) dkn311v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Giske, D. L. Monnet, O. Cars, Y. Carmeli, and on behalf of ReAct-Action on Antibiotic Resistance Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli Antimicrob. Agents Chemother., March 1, 2008; 52(3): 813 - 821. [Full Text] [PDF]
|
|
|
|
|
|
M. Castanheira, H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-{beta}-Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program Antimicrob. Agents Chemother., February 1, 2008; 52(2): 570 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
|
|
M. Grare, M. Mourer, S. Fontanay, J.-B. Regnouf-de-Vains, C. Finance, and R. E. Duval In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria J. Antimicrob. Chemother., September 1, 2007; 60(3): 575 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Slover, K. A Rodvold, and L. H Danziger Tigecycline: A Novel Broad-Spectrum Antimicrobial Ann. Pharmacother., June 1, 2007; 41(6): 965 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Scheetz, C. Qi, J. R. Warren, M. J. Postelnick, T. Zembower, A. Obias, and G. A. Noskin In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1621 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Insa, E. Cercenado, M. J. Goyanes, A. Morente, and E. Bouza In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia J. Antimicrob. Chemother., March 1, 2007; 59(3): 583 - 585. [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, B. A. Potoski, R. Rea, J. Adams, J. Sethi, B. Capitano, S. Husain, E. J. Kwak, S. V. Bhat, and D. L. Paterson Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report J. Antimicrob. Chemother., January 1, 2007; 59(1): 128 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P Holloway, N. G Rouphael, J. B Wells, M. D King, and H. M Blumberg Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit Ann. Pharmacother., November 1, 2006; 40(11): 1939 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Coelho, J. F. Turton, M. E. Kaufmann, J. Glover, N. Woodford, M. Warner, M.-F. Palepou, R. Pike, T. L. Pitt, B. C. Patel, et al. Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England. J. Clin. Microbiol., October 1, 2006; 44(10): 3623 - 3627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Jeffres, W. Isakow, J. A. Doherty, P. S. McKinnon, D. J. Ritchie, S. T. Micek, and M. H. Kollef Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care-Associated Pneumonia: Specific Evaluation of Vancomycin Pharmacokinetic Indices. Chest, October 1, 2006; 130(4): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Souli, F. V. Kontopidou, E. Koratzanis, A. Antoniadou, E. Giannitsioti, P. Evangelopoulou, S. Kannavaki, and H. Giamarellou In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek Hospitals. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3166 - 3169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, M. Garcia-Castillo, T. M. Coque, A. Valverde, A. Novais, E. Loza, F. Baquero, and R. Canton Antibiotic Coresistance in Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2695 - 2699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kasbekar Tigecycline: A new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|